Showing 3561-3570 of 5646 results for "".
- Sight Sciences Launches OMNI Edge Surgical System at ASCRShttps://modernod.com/news/sight-sciences-to-debut-omni-edge-surgical-system-at-ascrs/2482748/Sight Sciences announced the expansion of the OMNI product family by launching the OMNI Edge Surgical System. The new technology will debut at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, taking place April 25–27 in Los Angeles.<
- Applications Being Accepted for the 2025 Ramin Tadayoni Awardhttps://modernod.com/news/applications-being-accepted-for-the-2025-ramin-tadayoni-award/2482740/Oculis, in collaboration with EURETINA, announced that applications are now being accepted for the 2025 Ramin Tadayoni Award. The Ramin Tadayoni Award continues its legacy through EURETINA and has been supported by Oculis as a lasting tribute
- MST Enters Strategic Partnership with Mani to Distribute Ophthalmic Surgical Blade Portfolio in the UShttps://modernod.com/news/microsurgical-technology-mst-enters-strategic-partnership-with-mani-to-distribute-ophthalmic-surgical-blade-portfolio-in-the-us/2482739/Microsurgical Technology (MST) announced a strategic partnership with Mani Inc. under which MST will serve as a distributor of Mani’s ophthalmic surgical blade portfolio in the United States. The deal is supported by the establishment of Mani Medical America, the US
- Outlook Therapeutics Announces Acceptance of Resubmitted BLA by FDA for ONS-5010 as a Treatment for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-acceptance-of-resubmitted-bla-by-fda-for-ons-5010-as-a-treatment-for-wet-amd/2482733/Outlook Therapeutics announced that the FDA has acknowledged receipt of the resubmission of the biologics license application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD. The FDA has determined that the BLA
- Oculis Completes Enrollment in Both DIAMOND Phase 3 Trials of OCS-01 in DMEhttps://modernod.com/news/oculis-completes-enrollment-in-both-diamond-phase-3-trials-of-ocs-01-in-dme/2482732/Oculis Holding said it has completed enrollment in both phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME. The trials are designed as pivotal registration studies to support global marketing applications including NDA submission and approval by t
- Orasis Launches Presbyopia Eyedrop Qlosi in the UShttps://modernod.com/news/orasis-launches-presbyopia-eyedrop-qlosi-in-the-us/2482728/Orasis Pharmaceuticals announced that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel, corrective prescription eye drop for the treatment of presbyopia in adults is now available to prescribe in the US. Qlosi’s proprietary 'EyeQ Formulation&
- FDA Once Again Rejects Aldeyra's NDA of Reproxalap for Dry Eye Diseasehttps://modernod.com/news/fda-once-again-rejects-aldeyras-nda-of-reproxalap-for-dry-eye-disease/2482727/The FDA issued a complete response letter declining to approve Aldeyra Therapeutics' resubmitted new drug application (NDA) of reproxalap, an investigational drug candidate for the treatment of dry eye disease. Although no manufacturing or safety issues with repr
- Alcon Launches Clareon PanOptix Pro Trifocal IOLhttps://modernod.com/news/alcon-launches-clareon-panoptix-pro-trifocal-iol/2482725/Alcon has introduced the Clareon PanOptix Pro IOL in the US. According to Alcon, PanOptix Pro leverages proprietary 'ENLIGHTEN NXT' Optical technology, which is designed
- Hoya Launches VisuPro Advanced Focus Spectacle Lenses for Patients Experiencing Early Symptoms of Presbyopiahttps://modernod.com/news/hoya-launches-visupro-advanced-focus-spectacle-lenses-for-patients-experiencing-first-symptoms-of-presbyopia/2482724/Hoya has launched its VisuPro All Day and VisuPro Flex advanced focus spectacle lenses, which are designed to help people in their late 30s to mid-40s that are beginning to experience presbyopia. As people enter this age group, they may begi
- Alcon Acquires Majority Interest in Aurion Biotechhttps://modernod.com/news/alcon-acquires-majority-interest-in-aurion-biotech-to-advance-cell-therapy-for-corneal-endothelial-disease/2482718/Alcon announced it has acquired a majority interest in Aurion Biotech, a clinical-stage company developing cell therapies to treat eye diseases. Financial terms of the deal were not disclosed.